-transparent.png){kind=logo}
It was previously shown that the urinary sulfo-conjugate metabolite of cicletanine (cicletanine sulfate), and not free cicletanine, is salidiuretic in rats. Here we investigated potential differences between the resolved (+/-) enantiomers of cicletanine sulfate. Two groups of rats (n = 10) received either (+)- or (-)-cicletanine p.o. High performance capillary electrophoresis revealed that the 24-h urinary excretion of (+)-cicletanine sulfate was 5 times higher than that of (-)-cicletanine sulfate (18.9% vs. 3.8% of the oral dose). The same relative trend was observed after 5 and 10 days of oral administration. Following direct administration into the renal artery of anesthetized rats, (+)-cicletanine sulfate was 3-4 times more potent, in terms of active doses, than (-)-cicletanine sulfate to increase sodium excretion (ED50 = 1.86 +/- 0.28 mg/kg vs. 6.1 +/- 1.0 mg/kg, mean +/- S.E.M., n = 4). The maximal natriuretic potency of (+)-cicletanine sulfate was intermediate between that of furosemide and DIDS (4,4'-diisothiocyanostilbene-2,2'-disulfonate). In rat erythrocytes, (+)-cicletanine sulfate was between 2 and 3 times more potent to inhibit the Na(+)-dependent Cl-/HCO3- anion exchanger than (-)-cicletanine sulfate (IC50 = 61 +/- 3 microM vs. 142 +/- 31 microM, n = 4). In conclusion, (+)-cicletanine was more sulfo-conjugated and more potent natriuretic agent in rats than (-)-cicletanine. These results strongly suggest that (+)-cicletanine sulfate is the active natriuretic metabolite of racemic cicletanine in rats. This compound may probably act by inhibiting the Na(+)-dependent Cl-/HCO3- anion exchanger at the cortical diluting segment.
R P Garay, and
C Rosati, and
K Fanous, and
M Allard, and
E Morin, and
D Lamiable, and
R Vistelle
January 1982,
Science (New York, N.Y.),
R P Garay, and
C Rosati, and
K Fanous, and
M Allard, and
E Morin, and
D Lamiable, and
R Vistelle
September 1992,
The Journal of pharmacology and experimental therapeutics,
R P Garay, and
C Rosati, and
K Fanous, and
M Allard, and
E Morin, and
D Lamiable, and
R Vistelle
June 1966,
Biochemical pharmacology,
R P Garay, and
C Rosati, and
K Fanous, and
M Allard, and
E Morin, and
D Lamiable, and
R Vistelle
July 1991,
European journal of pharmacology,
R P Garay, and
C Rosati, and
K Fanous, and
M Allard, and
E Morin, and
D Lamiable, and
R Vistelle
January 2008,
Drug metabolism and pharmacokinetics,
R P Garay, and
C Rosati, and
K Fanous, and
M Allard, and
E Morin, and
D Lamiable, and
R Vistelle
February 1996,
The Journal of pharmacy and pharmacology,
R P Garay, and
C Rosati, and
K Fanous, and
M Allard, and
E Morin, and
D Lamiable, and
R Vistelle
May 1993,
Naunyn-Schmiedeberg's archives of pharmacology,
R P Garay, and
C Rosati, and
K Fanous, and
M Allard, and
E Morin, and
D Lamiable, and
R Vistelle
November 1990,
The Journal of investigative dermatology,
R P Garay, and
C Rosati, and
K Fanous, and
M Allard, and
E Morin, and
D Lamiable, and
R Vistelle
May 2004,
Clinical chemistry,
R P Garay, and
C Rosati, and
K Fanous, and
M Allard, and
E Morin, and
D Lamiable, and
R Vistelle
August 1991,
Biochemical and biophysical research communications,
